EB-1020 is a novel drug in Phase II clinical trials for the treatment of ADHD. It is under development by Neurovance, a spinout from Euthymics Biosciences. The drug is intended to function as a non-stimulant, acting as a triple reuptake inhibitor – preventing the reuptake of dopamine, norepinephrine, and serotonin.